Yan-min Zhao
Hangzhou, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
Changing donors improves outcomes of second transplantation in patients who experienced graft failure after first allogeneic stem cell transplantation.
Journal: Haematologica
Published: February 20, 2025
Epstein-Barr virus positive post-transplant lymphoproliferative disorder with significantly decreased T-cell chimerism early after transplantation: A case report.
Journal: World journal of radiology
Published: May 24, 2024
A novel risk model for predicting early relapse in acute myeloid leukemia patients undergoing allogeneic hematopoietic stem-cell transplantation.
Journal: Bone marrow transplantation
Published: December 03, 2022
Preemptive interferon-α therapy could prevent relapse of acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation: A real-world analysis.
Journal: Frontiers in immunology
Published: November 06, 2022
Comparable outcomes in patients with B-cell acute lymphoblastic leukemia receiving haploidentical hematopoietic stem cell transplantation: Pretransplant minimal residual disease-negative complete remission following chimeric antigen receptor T-cell therapy versus chemotherapy.
Journal: Frontiers in immunology
Published: May 02, 2022
Outcome after allogeneic hematopoietic stem cell transplantation following Venetoclax-based therapy among AML and MDS patients.
Journal: Annals of hematology
Published: March 02, 2022
Successful treatment of early onset Epstein-Barr virus-negative T-cell lymphoproliferative disorder after allogeneic hematopoietic stem cell transplantation with histone deacetylase inhibitor chidamide.
Journal: Chinese medical journal
Published: November 30, 2021
Zanubrutinib Treatment of Central Nervous System Posttransplant Lymphoproliferative Disorder After Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report.
Journal: Frontiers in oncology
Published: February 25, 2021
Preemptive low-dose interleukin-2 or DLI for late-onset minimal residual disease in acute leukemia or myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation.
Journal: Annals of hematology
Published: June 06, 2020
Different screening frequencies of carbapenem-resistant Enterobacteriaceae in patients undergoing hematopoietic stem cell transplantation: which one is better?
Journal: Antimicrobial resistance and infection control
Published: January 09, 2020
Rapamycin interacts synergistically with idarubicin to induce T-leukemia cell apoptosis in vitro and in a mesenchymal stem cell simulated drug-resistant microenvironment via Akt/mammalian target of rapamycin and extracellular signal-related kinase signaling pathways.
Journal: Leukemia & lymphoma
Published: June 08, 2013
Last Updated: 09/26/2026